Intercept Pharmaceuticals (NASDAQ:ICPT) Stock Rating Reaffirmed by B. Riley

Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “buy” rating reiterated by equities researchers at B. Riley in a research report issued on Thursday, TipRanks reports. They currently have a $158.00 price objective on the biopharmaceutical company’s stock. B. Riley’s target price indicates a potential upside of 133.38% from the company’s previous close.

Several other research analysts have also issued reports on ICPT. Needham & Company LLC reiterated a “buy” rating and set a $150.00 price objective on shares of Intercept Pharmaceuticals in a research note on Tuesday, December 17th. Wedbush reiterated a “buy” rating and set a $257.00 price objective on shares of Intercept Pharmaceuticals in a research note on Thursday, February 27th. Robert W. Baird reiterated a “buy” rating and set a $227.00 price objective on shares of Intercept Pharmaceuticals in a research note on Tuesday, December 17th. BidaskClub lowered Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $186.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $146.18.

Shares of ICPT stock opened at $67.70 on Thursday. The stock has a market cap of $2.22 billion, a P/E ratio of -6.22 and a beta of 1.54. Intercept Pharmaceuticals has a one year low of $47.57 and a one year high of $125.00. The stock has a fifty day moving average price of $83.51 and a 200 day moving average price of $88.43. The company has a debt-to-equity ratio of 10.32, a current ratio of 4.45 and a quick ratio of 4.45.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Tuesday, February 25th. The biopharmaceutical company reported ($2.99) EPS for the quarter, missing the consensus estimate of ($2.52) by ($0.47). The firm had revenue of $71.50 million during the quarter, compared to the consensus estimate of $68.19 million. Intercept Pharmaceuticals had a negative return on equity of 455.79% and a negative net margin of 136.78%. The firm’s revenue for the quarter was up 34.2% compared to the same quarter last year. During the same period last year, the business earned ($2.97) earnings per share. Equities research analysts anticipate that Intercept Pharmaceuticals will post -11.01 EPS for the current year.

In other news, insider Jason Campagna sold 732 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $113.02, for a total value of $82,730.64. Following the completion of the sale, the insider now directly owns 6,303 shares in the company, valued at $712,365.06. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David A. Ford sold 259 shares of the firm’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $117.16, for a total value of $30,344.44. Following the completion of the sale, the insider now owns 10,945 shares of the company’s stock, valued at $1,282,316.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,827 shares of company stock valued at $190,967. 5.00% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Edge Wealth Management LLC bought a new position in Intercept Pharmaceuticals in the fourth quarter valued at about $37,000. Nisa Investment Advisors LLC boosted its holdings in Intercept Pharmaceuticals by 200.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 300 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 200 shares during the last quarter. Kistler Tiffany Companies LLC boosted its holdings in Intercept Pharmaceuticals by 33.3% in the fourth quarter. Kistler Tiffany Companies LLC now owns 400 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 100 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in Intercept Pharmaceuticals in the third quarter valued at about $36,000. Finally, Sowell Financial Services LLC boosted its holdings in Intercept Pharmaceuticals by 469.6% in the fourth quarter. Sowell Financial Services LLC now owns 655 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 540 shares during the last quarter. Institutional investors own 78.66% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Read More: Back-End Load

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mitchell Mcleod Pugh & Williams Inc. Has $252,000 Holdings in General Electric
Mitchell Mcleod Pugh & Williams Inc. Has $252,000 Holdings in General Electric
Mitchell Mcleod Pugh & Williams Inc. Acquires 500 Shares of Starbucks Co.
Mitchell Mcleod Pugh & Williams Inc. Acquires 500 Shares of Starbucks Co.
Bank of America  PT Lowered to $20.00 at UBS Group
Bank of America PT Lowered to $20.00 at UBS Group
IFM Investors Pty Ltd Sells 5,253 Shares of Walmart Inc
IFM Investors Pty Ltd Sells 5,253 Shares of Walmart Inc
Macquarie Group Ltd. Has $2.83 Million Position in Valero Energy Co.
Macquarie Group Ltd. Has $2.83 Million Position in Valero Energy Co.
Marquette Asset Management LLC Increases Stock Position in Boeing Co
Marquette Asset Management LLC Increases Stock Position in Boeing Co


© 2006-2020 Ticker Report